Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2013 1
2014 4
2015 3
2016 4
2017 1
2018 2
2019 4
2020 5
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Results by year
Filters applied: . Clear all
Page 1
Showing results for stephan tschirdewahn
Your search for Stephan Schirdewahn retrieved no results
[Upper urinary tract cancer].
Tschirdewahn S, Rübben H. Tschirdewahn S, et al. Urologe A. 2019 Jan;58(1):3-4. doi: 10.1007/s00120-018-0827-8. Urologe A. 2019. PMID: 30666375 German. No abstract available.
The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer.
Darr C, Krafft U, Hadaschik B, Tschirdewahn S, Sevcenco S, Csizmarik A, Nyirady P, Küronya Z, Reis H, Maj-Hes A, Shariat SF, Kramer G, Szarvas T. Darr C, et al. Among authors: tschirdewahn s. Urol Int. 2018;101(1):65-73. doi: 10.1159/000489891. Epub 2018 Jun 27. Urol Int. 2018. PMID: 29949801
Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer.
Krafft U, Tschirdewahn S, Hess J, Harke NN, Hadaschik B, Olah C, Krege S, Nyirády P, Szendröi A, Szücs M, Módos O, Székely E, Reis H, Szarvas T. Krafft U, et al. Among authors: tschirdewahn s. Urol Oncol. 2019 Nov;37(11):810.e7-810.e15. doi: 10.1016/j.urolonc.2019.04.015. Epub 2019 Apr 30. Urol Oncol. 2019. PMID: 31053526
External validation of novel magnetic resonance imaging-based models for prostate cancer prediction.
Püllen L, Radtke JP, Wiesenfarth M, Roobol MJ, Verbeek JFM, Wetter A, Guberina N, Pandey A, Hüttenbrink C, Tschirdewahn S, Pahernik S, Hadaschik BA, Distler FA. Püllen L, et al. Among authors: tschirdewahn s. BJU Int. 2020 Mar;125(3):407-416. doi: 10.1111/bju.14958. Epub 2019 Dec 20. BJU Int. 2020. PMID: 31758738
Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.
Tschirdewahn S, Panic A, Püllen L, Harke NN, Hadaschik B, Riesz P, Horváth A, Szalontai J, Nyirády P, Baba HA, Reis H, Szarvas T. Tschirdewahn S, et al. Int J Cancer. 2019 Jul 15;145(2):531-539. doi: 10.1002/ijc.32124. Epub 2019 Jan 31. Int J Cancer. 2019. PMID: 30650187 Free article.
Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging.
Al-Bayati M, Grueneisen J, Lütje S, Sawicki LM, Suntharalingam S, Tschirdewahn S, Forsting M, Rübben H, Herrmann K, Umutlu L, Wetter A. Al-Bayati M, et al. Among authors: tschirdewahn s. Urol Int. 2018;100(2):164-171. doi: 10.1159/000484695. Epub 2018 Jan 25. Urol Int. 2018. PMID: 29393268
Serum Chromogranin A as a Complementary Marker for the Prediction of Prostate Cancer-Specific Survival.
Niedworok C, Tschirdewahn S, Reis H, Lehmann N, Szücs M, Nyirády P, Romics I, Rübben H, Szarvas T. Niedworok C, et al. Among authors: tschirdewahn s. Pathol Oncol Res. 2017 Jul;23(3):643-650. doi: 10.1007/s12253-016-0171-5. Epub 2016 Dec 23. Pathol Oncol Res. 2017. PMID: 28012116
Serum and tissue syndecan-1 levels in renal cell carcinoma.
Niedworok C, Kempkensteffen C, Eisenhardt A, Tschirdewahn S, Rehme C, Panic A, Reis H, Baba H, Nyirády P, Hadaschik B, Kovalszky I, Szarvas T. Niedworok C, et al. Among authors: tschirdewahn s. Transl Androl Urol. 2020 Jun;9(3):1167-1176. doi: 10.21037/tau-19-787. Transl Androl Urol. 2020. PMID: 32676400 Free PMC article.
Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer.
Vom Dorp F, Tschirdewahn S, Niedworok C, Reis H, Krause H, Kempkensteffen C, Busch J, Kramer G, Shariat SF, Nyirady P, Rübben H, Szarvas T. Vom Dorp F, et al. Among authors: tschirdewahn s. J Urol. 2016 Apr;195(4 Pt 1):1120-5. doi: 10.1016/j.juro.2015.09.084. Epub 2015 Oct 8. J Urol. 2016. PMID: 26454102
Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancer.
Szarvas T, Reis H, Vom Dorp F, Tschirdewahn S, Niedworok C, Nyirady P, Schmid KW, Rübben H, Kovalszky I. Szarvas T, et al. Among authors: tschirdewahn s. Prostate. 2016 Aug;76(11):977-85. doi: 10.1002/pros.23186. Epub 2016 Apr 7. Prostate. 2016. PMID: 27062540
21 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback